Hydromorphone — sold under the brand name Dilaudid and others — is a potent semi-synthetic opioid analgesic that is significantly more powerful than morphine and widely used in hospital settings for severe acute pain and cancer pain. Despite its relatively low profile outside of medical settings compared to drugs like OxyContin or Vicodin, hydromorphone is one of the most important clinical opioids in hospital formularies, emergency departments, and palliative care settings worldwide.
What Is Hydromorphone?
Hydromorphone is a semi-synthetic opioid derived from morphine, first synthesized in Germany in 1921 and introduced to medicine in the 1920s. It is the hydrogenated ketone of morphine — hence the name hydromorphone. Compared to morphine, it has significantly greater analgesic potency, higher water solubility, and a shorter duration of action, properties that make it highly suitable for both IV infusion and patient-controlled analgesia (PCA) pumps in hospital settings.
Brand names include Dilaudid (oral tablets and injectable), Exalgo (extended-release tablets), and various generics. It is available in: immediate-release oral tablets (2 mg, 4 mg, 8 mg), oral liquid (1 mg/mL), injectable solution (1–4 mg/mL, high-potency 10 mg/mL), rectal suppositories, and extended-release tablets (Exalgo 8–64 mg).
How Hydromorphone Works
Hydromorphone is a selective full agonist at mu-opioid receptors, with activity also at delta opioid receptors. Its high receptor affinity and potency translate to effective analgesia at doses much smaller than morphine. The key pharmacological differences from morphine include:
- Potency: 5–10 times more potent than morphine by oral weight; approximately 4–5 times by IV weight (1.5 mg IV hydromorphone ≈ 7.5 mg IV morphine)
- Higher water solubility than morphine — important for concentrated subcutaneous infusions in palliative care
- Less histamine release than morphine — reduced risk of pruritus and allergic-type reactions
- No clinically significant active metabolites accumulating in renal failure (unlike morphine's M6G) — making it safer in patients with kidney disease
- Shorter duration: IV hydromorphone peaks in 5–10 minutes; effect duration 3–4 hours for immediate-release forms
- Half-life: 2.3 hours (shorter than morphine's 3–4 hours)
Medical Uses of Hydromorphone
Acute Severe Pain
Hydromorphone is a first-choice opioid in emergency departments and hospitals for severe acute pain — including major trauma, burns, renal colic (kidney stones), sickle cell crisis, and post-operative pain. Its rapid IV onset (5 minutes to peak effect) and predictable dose-response make it highly controllable for acute pain management. Many emergency physicians prefer IV hydromorphone to IV morphine for severe pain due to its faster onset and perceived better tolerability.
Cancer Pain
Hydromorphone is a primary alternative to morphine for cancer pain management, particularly in patients who have developed intolerance or insufficient response to morphine. The WHO and NCCN guidelines both recognize hydromorphone as a strong opioid for moderate to severe cancer pain. Its high solubility is particularly valuable for subcutaneous continuous infusion in palliative care settings where IV access is not available.
Chronic Non-Cancer Pain
Extended-release hydromorphone (Exalgo) is approved for around-the-clock management of pain severe enough to require daily opioid therapy in opioid-tolerant patients. Exalgo uses osmotic drug delivery to release hydromorphone slowly over 24 hours, allowing once-daily dosing.
Renal Impairment Patients
Hydromorphone is often the preferred opioid for patients with chronic kidney disease, because its primary metabolite (hydromorphone-3-glucuronide, H3G) does not produce the same clinically significant analgesic or respiratory depression seen with morphine's M6G. While H3G can accumulate and cause neuroexcitatory effects (agitation, myoclonus) in severe renal failure, this is more manageable than morphine's accumulation risks.
Hydromorphone Dosage
| Route | Opioid-Naive Starting Dose | Interval | Notes |
|---|---|---|---|
| Oral immediate-release | 2–4 mg | Every 4–6 hours | Take with food to reduce nausea |
| IV bolus (acute pain) | 0.2–0.6 mg | Every 2–4 hours | Slower injection reduces side effects |
| IV PCA | 0.1–0.2 mg demand dose | 6–10 min lockout | Standard hospital PCA protocol |
| SC infusion (palliative) | 2–4 mg/day | Continuous | Highly concentrated solutions possible |
| Extended-release oral (Exalgo) | 8 mg once daily | Every 24 hours | Opioid-tolerant patients only |
Side Effects of Hydromorphone
- Constipation — universal, does not improve with tolerance
- Nausea and vomiting (less than some other opioids)
- Sedation and CNS depression
- Respiratory depression — potentially fatal in overdose
- Pruritus — less common than with morphine due to lower histamine release
- Dizziness and orthostatic hypotension
- Urinary retention
- Myoclonus (muscle jerking) — with high doses or renal impairment; related to H3G accumulation
- Hormonal suppression with chronic use
- Physical dependence and addiction risk
Hydromorphone vs Morphine: Clinical Comparison
| Feature | Hydromorphone (Dilaudid) | Morphine |
|---|---|---|
| Relative potency | 5–10x more potent (oral) | Reference (1x) |
| Oral bioavailability | ~30–40% | ~20–40% |
| IV onset to peak | 5–10 minutes | 15–30 minutes |
| Duration (IV) | 3–4 hours | 4–5 hours |
| Histamine release | Minimal | Moderate |
| Renal safety | Better (H3G less dangerous than M6G) | Caution required |
| Solubility | Very high — ideal for concentrated infusions | Moderate |
| Half-life | ~2.3 hours | ~2–4 hours |
Drug Interactions
- Benzodiazepines and CNS depressants — highly dangerous; potentiates respiratory depression
- Alcohol — additive CNS and respiratory depression
- MAO inhibitors — contraindicated; severe adverse reactions possible
- Anticholinergics — additive constipation and urinary retention
- Other opioids — additive respiratory depression; generally not co-prescribed